Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Patient Insights into the Design of Technology to Support a Strengths-Based Approach to Health Care.

SURVEY: Weight Management & Chronic Illness

Japanese green tea consumers have reduced risk of dementia

Do Nothing, Accomplish Everything! The Connection Between Breathing and Healing

Meet the ProHealth Editors

Best Herbs to Help With Insomnia

Choline: Why You Should Eat Your Egg Yolks and Take Krill

Calcium, vitamin D supplementation associated improved stroke recovery

Acupressure reduced fatigue in breast cancer survivors

More positive evidence for melatonin in breast cancer battle

 
Print Page
Email Article

Merck Denies Vioxx Linked to Eleven Deaths

  [ 10 votes ]   [ Discuss This Article ]
By Deborah Cooper • www.ProHealth.com • September 19, 2000


Eleven patients using Vioxx have died in Britain according to a UK drug regulatory body, but the drug manufacturer Merck & Co. deny its arthritis drug was linked to the mortalities.

In addition to the deaths the UK’s regulatory bodies, the Medicines Control Agency and the Committee on the Safety of Medicines has received 1,120 reports of adverse effects to rofecoxib, the generic name for Vioxx.

According to the report published in the agency's September newsletter Current Problems, “Gastrointestinal (GI) adverse reactions account for almost half (554) of the reports, of which the majority were nausea, dyspepsia, diarrhea and abdominal pain. However, there have been 68 reports of upper GI perforations, ulcerations and bleeds (PUBs). Forty-four of the patients with PUBs recovered, although five had a fatal outcome.”

It is these five fatalities, along with six other deaths in people with possible cardiac failure and among people with a high risk factor for cardiovascular disease, that has raised the alarm for prescribers and consumers alike.

The other deaths mentioned in the report were part of a total of 192 incidences of suspected cardiovascular reactions, including 15 reports of cardiac failure, 101 reports of edema and 19 reports of palpitations.

Merck & Co., the US drug giant, said that none of the deaths was linked to the medicine. A spokeswoman for the company, Mary Elizabeth Basaman said “There is not a cause and effect. They’re not attributing anything to a specific drug.” Another Merck official, Eve Slater, added, “The report…is no cause for concern.”

The drug maker also pointed out that eleven deaths in a large aging population should not be considered remarkable.

However, the regulatory agency's report concluded with a cautious note. “As with all new drugs, the safety of refocoxib remains under close review.”

An estimated 557,100 prescriptions for Vioxx were dispensed in Britain up to the end of May 2000. The rate of reported adverse reactions is approximately one per 500 prescriptions.

Vioxx is approved in the US and UK as a treatment for osteoarthritis, the most common form of arthritis affecting more than 16 million Americans. Its competitor is another drug also in the same class of non steroidal anti-inflammatory drugs, the Cox-2 inhibitor Celebrex, manufactured by Pharmacia Corp. Last year, Celebrex reached $1.5 billion in sales and Vioxx, launched four months later, garnered $472 million. Both drugs are considered safer and easier to handle than some older arthritis medications such as aspirin.

Rofecoxib (Vioxx) does come with warnings that it is contraindicated in patients with active peptic ulceration or GI bleeding, as well as for patients with severe congestive heart failure. Caution is also urged for users who have a history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing edema for any other reason.



Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Optimized Curcumin Longvida® Ultra ATP+, Double Strength

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Could a B-12 Deficiency Be Causing Your Symptoms? Could a B-12 Deficiency Be Causing Your Symptoms?
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
Secret Nutrient for Radiant Skin Secret Nutrient for Radiant Skin
Herbal Rescue for High Blood Sugar Herbal Rescue for High Blood Sugar
Astaxanthin - A Little-Known but Power-Packed Nutrient Astaxanthin - A Little-Known but Power-Packed Nutrient

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map